Yahoo Finance • 7 days ago
Châtillon, France, September 18, 2025 DBV Technologies Announces Resignation of Board Member DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical compan... Full story
Yahoo Finance • 7 days ago
Châtillon, France, le 18 septembre 2025 DBV Technologies annonce la démission d’un membre de son Conseil d’administration DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (la “Société” ou “DBV”), une société b... Full story
Yahoo Finance • 20 days ago
* DBV Technologies (NASDAQ:DBVT [https://seekingalpha.com/symbol/DBVT]) filed a prospectus supplement with the SEC for an at-the-market offering up to $150M of American Depositary Shares. * Each ADS represents five ordinary shares of t... Full story
Yahoo Finance • 20 days ago
Châtillon, France, September 5, 2025 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceu... Full story
Yahoo Finance • 20 days ago
Châtillon, France, le 5 septembre (22:30 CEST) 2025 DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Capital Market : DBVT) (la « Société »), une... Full story
Yahoo Finance • 22 days ago
Châtillon, France, September 3, 2025 DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a... Full story
Yahoo Finance • 22 days ago
Châtillon, France, le 3 septembre (22:30 CEST) 2025 DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP :... Full story
Yahoo Finance • 2 months ago
Châtillon, France, July 29, 2025 DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical... Full story
Yahoo Finance • 2 months ago
Châtillon, France, le 29 juillet 2025 DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une société... Full story
Yahoo Finance • 2 months ago
Châtillon, France, July 29, 2025 DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharm... Full story
Yahoo Finance • 2 months ago
Châtillon, France, le 29 juillet 2025 DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025 DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Stock Market : DBVT-CUSIP : 23306J309), société... Full story
Yahoo Finance • 2 months ago
AMF Regulated Information Châtillon, France, July 28, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage bio... Full story
Yahoo Finance • 2 months ago
Informations Réglementées Châtillon, France, le 28 juillet (22 h 30 CET) 2025 Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT), laboratoire b... Full story
Yahoo Finance • 3 months ago
DBV Technologies (NASDAQ:DBVT) S.A., a biopharmaceutical company focused on developing treatments for food allergies, has been making significant strides in its quest to bring Viaskin Peanut to market. The company’s stock has shown remark... Full story
Yahoo Finance • 2 years ago
DBV Technologies S.A. Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)... Full story
Yahoo Finance • 3 years ago
DBV Technologies S.A. Montrouge, France, March 7, 2023 DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old First patient screened at Midwest Allergy Sinus Asthm... Full story
Yahoo Finance • 3 years ago
DBV Technologies S.A. Montrouge, France, October 31, 2022 DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a... Full story
Yahoo Finance • 3 years ago
The biotech industry is volatile. Case in point: Axsome Therapeutics (NASDAQ: AXSM) and DBV Technologies (NASDAQ: DBVT) -- two small-cap biotechs -- recently saw their shares explode following positive developments. Here is the rundown on... Full story
Yahoo Finance • 3 years ago
DBV Technologies S.A. Montrouge, France, May 12, 2022 DBV Technologies Announces Results of Its 2022Ordinary and Extraordinary General Meeting Shareholders ApprovedAll Proposed Resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010... Full story
Yahoo Finance • 3 years ago
Montrouge, France, May 2, 2022 DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results The U.S. Food and Drug Administration (FDA) has granted DBV Technologies a Type C meeting to align on the new V... Full story